Prolonged-Release Fampridine Treatment and Walking Ability and Balance in Patients with Multiple Sclerosis: Results of the Randomized, Double-Blind MOBILE Study

被引：0
|
作者：
Lycke, Jan
Short, Christine
Gasperini, Claudio
Hupperts, Raymond
McNeil, Manjit
Medori, Rossella
Mehta, Lahar
Elkins, Jacob
机构：
来源：
NEUROLOGY | 2014年 / 83卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：E36 / E36
页数：1
相关论文
共 50 条
  • [31] Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study
    Castelnovo, Giovanni
    Gerlach, Oliver
    Freedman, Mark S.
    Bergmann, Arnfin
    Sinay, Vladimiro
    Castillo-Trivino, Tamara
    Kong, George
    Koster, Thijs
    Williams, Heather
    Gafson, Arie R.
    Killestein, Joep
    CNS DRUGS, 2021, 35 (09) : 1009 - 1022
  • [32] Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study
    Giovanni Castelnovo
    Oliver Gerlach
    Mark S. Freedman
    Arnfin Bergmann
    Vladimiro Sinay
    Tamara Castillo-Triviño
    George Kong
    Thijs Koster
    Heather Williams
    Arie R. Gafson
    Joep Killestein
    CNS Drugs, 2021, 35 : 1009 - 1022
  • [33] Walking, quality of life, and safety with prolonged-release fampridine treatment in clinical practice: Interim results of the liberate study
    Schmidt, S.
    Oschmann, P.
    Neau, J. P.
    Castelnovo, G.
    Wang, P.
    Barbato, L.
    Mahadavan, L.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 357 : E21 - E21
  • [34] Safety, Patient Reported Outcomes, and Clinical Assessment on Walking Ability Of Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study
    Castelnovo, G.
    Hupperts, R.
    Freedman, M. S.
    Bergmann, A.
    Sinay, V.
    Trivino, T. C.
    Kong, G.
    Koster, T.
    Williams, H.
    Zhu, B.
    Killestein, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 203 - 203
  • [35] Prolonged-release fampridine and active motor training in MS patients: a Phase IV, double-blind, placebo-controlled
    Jacques, F. H.
    Nativ, A.
    Schembri, A. J.
    Paquette, C.
    Kalinowski, P.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 698 - 698
  • [36] Efficacy of prolonged-release fampridine vs placebo on walking ability, dynamic and static balance and quality-of-life: an integrated analysis of MOBILE and ENHANCE
    Hupperts, R.
    Hobart, J.
    Gasperini, C.
    Lycke, J.
    Ziemssen, T.
    Feys, P.
    McNeill, M.
    Acosta, C.
    Meergans, M.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 315 - 315
  • [37] Effects of prolonged-release fampridine on leg muscle activity during treadmill walking in individuals with multiple sclerosis (FAMPKIN)
    Loerincz, L.
    Zoerner, B.
    Weller, D.
    Reuter, K.
    Kapitza, S.
    Farkas, M.
    Sutter, T.
    Filli, L.
    Linnebank, M.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 608 - 608
  • [38] Sustained clinically meaningful improvements in walking ability with prolonged-release fampridine: results from the placebo-controlled ENHANCE study.
    Hobart, J.
    Ziemssen, T.
    Feys, P.
    Linnebank, M.
    Goodman, A.
    Farrell, R.
    Englishby, V.
    McNeill, M.
    Chang, I.
    Mehta, L.
    Elkins, J.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 833 - 834
  • [39] Prolonged-release fampridine treatment improved patient-perceived physical health impact of multiple sclerosis
    Mehta, L.
    Lycke, J.
    Gasperini, C.
    McNeill, M.
    Zhong, J.
    Elkins, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 660 - 660
  • [40] A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder
    Kasper, S
    Olivieri, L
    Di Loreto, G
    Dionisio, P
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (08) : 1139 - 1146
12345